Dietary Caloric Deficit Alone Cannot Overcome Immune-Driven Inflammation and Insulin Resistance
The speaker makes the claim that caloric restriction remains necessary but is insufficient when the immune system is chronically inflamed, stating 'you can't out-diet an immune system on fire.' This is used to justify the GLP-1 + LDN combination protocol over diet alone or GLP-1 alone. No quantitative data, study citations, or patient outcome metrics are provided.
GLP-1 + LDN Combination Stack: Synergistic Protocol for Inflamed and Autoimmune Patients
The speaker recommends pairing a GLP-1 agonist with LDN as a two-drug protocol, framing GLP-1 as symptom management and LDN as root-cause treatment. The claim is that LDN reduces immune-driven inflammation, which then allows the GLP-1's insulin-sensitizing and weight-loss benefits to fully manifest. No dosages, titration schedules, contraindications, or clinical study references are provided for the combination.
LDN (Low Dose Naltrexone) Targets Root-Cause Immune Overactivation to Reduce Inflammation
The speaker describes LDN (Low Dose Naltrexone) as attacking the source of inflammation by calming an overactive immune response, thereby stopping inflammation from being continuously regenerated. This is contrasted with GLP-1's symptom-management role. No dosage, frequency, or clinical evidence is cited. Note: LDN is not a peptide but is presented here as part of a peptide-adjacent stacking protocol.